Placebo News and Research

RSS

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

The LIVE-AIR phase 3 clinical trial is associated with early treatment of hyperinflammatory response with the humanized monoclonal antibody lenzilumab in COVID-19 patients with decreased oxygen saturation. The study results are posted to the medRxiv* preprint server.

6 Jan 2022

Monoclonal antibody treatment of COVID-19 reduces viral shedding

Researchers aim to understand the potential benefits of mAbs in preventing and treating SARS-CoV-2 infection.

5 Jan 2022

New compound could combat multidrug-resistant pathogens in healthcare settings

For years, public-health experts have been sounding the alarm about the next phase in humanity's co-existence with bacteria - a dark future where emerging strains have rendered once-powerful antibiotics useless.

5 Jan 2022

Research demonstrates the safety, feasibility of psilocybin administered at doses of 10mg or 25mg

New research from the Institute of Psychiatry, Psychology, & Neuroscience (IoPPN) at King's College London, in partnership with COMPASS Pathways, has established that psilocybin can be safely administered at doses of either 10mg or 25mg to up to six participants simultaneously.

4 Jan 2022

Echinacea, a potent antiviral against SARS-CoV-2

Researchers present available evidence on the activity of Echinacea purpure against coronavirus infections.

3 Jan 2022

New systematic review finds low-quality evidence on the effectiveness of hangover remedies

A new systematic review has found only very low-quality evidence that substances claiming to treat or prevent alcohol-induced hangover work.

3 Jan 2022

A reliable assessment of COVID-19 vaccine protection duration

Researchers from the University of North Carolina, University of Washington, and the US Food and Drug Administration propose fitting a Cox model with two time indexes, the event times measured from the start of the study in calendar time and the log hazard for the vaccine effect.

30 Dec 2021

Exploring immunogenicity and safety after a homologous booster dose of SARS-CoV-2 recombinant spike protein vaccine

Research suggests that a single booster dose of NVX-CoV2373 given approximately six months after the primary series induced significant increases in humoral antibodies, while also exhibiting an acceptable safety profile.

29 Dec 2021

Inhaled CBD shrinks glioblastoma’s size in an animal model

Inhaled CBD shrinks the size of the highly aggressive, lethal brain tumor glioblastoma in an animal model by reducing the essential support of its microenvironment, researchers report.

24 Dec 2021

Ad5-nCoV vaccine safe and effective against symptomatic, severe COVID-19, trials shows

One dose of Ad5-nCoV (Convidecia), a COVID-19 vaccine developed in China, is 57.5% effective against symptomatic COVID-19 and 91.7% effective against severe COVID-19 disease beginning 28 days postvaccination, according to a phase 3 randomized controlled trial published in The Lancet.

23 Dec 2021

Study points toward an alternative drug strategy to stall Alzheimer’s neurodegeneration

Boosting levels of the neurotransmitter norepinephrine with atomoxetine, a repurposed ADHD medication, may be able to stall neurodegeneration in people with early signs of Alzheimer's disease, a study conducted at Emory Brain Health Center suggests.

22 Dec 2021

Clinical trial results do not support the use of fish oil supplements to prevent depression

Results from the largest clinical trial of its kind do not support the use of fish oil supplements - a source of omega-3 fatty acid - to help prevent depression.

21 Dec 2021

Doctors advised to prescribe fewer antidepressants and for shorter periods of time

Doctors should prescribe fewer antidepressants and for shorter periods of time, because of the ongoing uncertainties about their effectiveness and the potential severity and durability of the withdrawal symptoms associated with them, suggests a review of the evidence on antidepressant use, published online in the Drug and Therapeutics Bulletin.

21 Dec 2021

Early administration of SARS-CoV-2 convalescent plasma reduces outpatient hospitalizations

The results of a nationwide, multicenter clinical trial led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health provides solid evidence for the use of plasma from convalescent patients — those who have recovered from the disease and whose blood contains antibodies against SARS-CoV-2, the virus that causes COVID-19 — as an early treatment.

21 Dec 2021

Women who took four weeks of prebiotic supplements consumed less sugar, study finds

A new study from the University of Surrey has found that young women who took four weeks of prebiotic supplements made healthier food choices and consumed less sugar.

21 Dec 2021

SGLT2 inhibitor empagliflozin can be used to treat insulin resistance in the brain, finds study

Overweight or obesity, an unfavorable distribution of fat in the body and the development of type 2 diabetes are often associated with a reduced effect of the hormone insulin in many organs, including the brain (insulin resistance).

21 Dec 2021

New oral pill for COVID-19 home treatment

As cases and hospitalizations continue to rise in many countries, new treatments are being sought to arrest the progression of the disease, preventing severe illness and death or disability. One such is the small molecule molnupiravir, the focus of a new research paper.

20 Dec 2021

Anti-SARS-CoV-2 antibody infusion shown to demonstrate robust immune response following COVID-19 vaccination

A new study expands the understanding of the impact of receiving a prophylactic monoclonal antibody infusion, as well as other variables, on the endogenous immune response to complete COVID-19 immunization.

20 Dec 2021

Study examines the effects of methylphenidate on mental fatigue in multiple sclerosis patients

A team of researchers at Kessler Foundation studied the effects of methylphenidate on mental fatigue in individuals with multiple sclerosis (MS). This is the first study to examine the psychostimulant's effects on 'state' vs 'trait' mental fatigue in MS.

18 Dec 2021

Efficacy of NVX-CoV2373 in the US and Mexican adult population

A new study has described the results of PREVENT-19, a phase 3 trial of NVX-CoV2373 that included all adults in the United States and Mexico.

17 Dec 2021

Placebo News and Research

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

Monoclonal antibody treatment of COVID-19 reduces viral shedding

New compound could combat multidrug-resistant pathogens in healthcare settings

Research demonstrates the safety, feasibility of psilocybin administered at doses of 10mg or 25mg

Echinacea, a potent antiviral against SARS-CoV-2

New systematic review finds low-quality evidence on the effectiveness of hangover remedies

A reliable assessment of COVID-19 vaccine protection duration

Exploring immunogenicity and safety after a homologous booster dose of SARS-CoV-2 recombinant spike protein vaccine

Inhaled CBD shrinks glioblastoma’s size in an animal model

Ad5-nCoV vaccine safe and effective against symptomatic, severe COVID-19, trials shows

Study points toward an alternative drug strategy to stall Alzheimer’s neurodegeneration

Clinical trial results do not support the use of fish oil supplements to prevent depression

Doctors advised to prescribe fewer antidepressants and for shorter periods of time

Early administration of SARS-CoV-2 convalescent plasma reduces outpatient hospitalizations

Women who took four weeks of prebiotic supplements consumed less sugar, study finds

SGLT2 inhibitor empagliflozin can be used to treat insulin resistance in the brain, finds study

New oral pill for COVID-19 home treatment

Anti-SARS-CoV-2 antibody infusion shown to demonstrate robust immune response following COVID-19 vaccination

Study examines the effects of methylphenidate on mental fatigue in multiple sclerosis patients

Efficacy of NVX-CoV2373 in the US and Mexican adult population

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News